Dynamic Advisor Solutions LLC Cuts Stake in AstraZeneca PLC (NASDAQ:AZN)

Dynamic Advisor Solutions LLC decreased its position in AstraZeneca PLC (NASDAQ:AZN) by 42.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,244 shares of the company’s stock after selling 6,123 shares during the period. Dynamic Advisor Solutions LLC’s holdings in AstraZeneca were worth $540,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. McClarren Financial Advisors Inc. boosted its holdings in AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares in the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of AstraZeneca in the third quarter valued at approximately $28,000. Albion Financial Group UT grew its holdings in AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after acquiring an additional 248 shares during the period. Groupama Asset Managment raised its position in AstraZeneca by 22.9% in the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after acquiring an additional 101,225 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in AstraZeneca in the third quarter valued at $45,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on AZN shares. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, AstraZeneca has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Stock Performance

NASDAQ:AZN opened at $70.08 on Tuesday. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $217.32 billion, a P/E ratio of 33.53, a price-to-earnings-growth ratio of 1.13 and a beta of 0.46. The firm has a 50-day moving average price of $66.44 and a two-hundred day moving average price of $74.14. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.87 EPS. As a group, research analysts expect that AstraZeneca PLC will post 4.12 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.